OptimizeRx (NASDAQ:OPRX) Stock Rating Lowered by Wall Street Zen

OptimizeRx (NASDAQ:OPRX) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Monday.

Several other research firms have also issued reports on OPRX. Lake Street Capital decreased their price target on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Zacks Research lowered shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 4th. B. Riley Financial cut their price objective on shares of OptimizeRx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Stifel Nicolaus reduced their target price on shares of OptimizeRx from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Finally, UBS Group set a $10.00 target price on OptimizeRx in a research report on Wednesday, May 13th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, OptimizeRx has a consensus rating of “Moderate Buy” and a consensus price target of $13.43.

OptimizeRx Price Performance

OPRX opened at $6.69 on Monday. The business has a 50 day moving average of $5.46 and a 200-day moving average of $7.51. The stock has a market capitalization of $125.50 million, a price-to-earnings ratio of 19.11 and a beta of 1.08. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.16. OptimizeRx has a 1-year low of $4.54 and a 1-year high of $22.25.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The business had revenue of $19.84 million for the quarter, compared to analyst estimates of $18.74 million. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. As a group, sell-side analysts anticipate that OptimizeRx will post 0.51 earnings per share for the current year.

Institutional Investors Weigh In On OptimizeRx

A number of institutional investors have recently bought and sold shares of the business. Segall Bryant & Hamill LLC bought a new stake in OptimizeRx in the 1st quarter valued at $1,185,000. Quantinno Capital Management LP raised its stake in shares of OptimizeRx by 180.1% in the 1st quarter. Quantinno Capital Management LP now owns 49,022 shares of the company’s stock valued at $308,000 after buying an additional 31,518 shares in the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of OptimizeRx by 1.9% during the 1st quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock worth $3,780,000 after acquiring an additional 11,247 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of OptimizeRx by 633.2% during the 1st quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock worth $1,362,000 after acquiring an additional 187,278 shares during the period. Finally, Sei Investments Co. lifted its holdings in shares of OptimizeRx by 83.4% during the 1st quarter. Sei Investments Co. now owns 98,633 shares of the company’s stock worth $619,000 after acquiring an additional 44,844 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.